CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

In the never-ending quest to discover previously unknown CRISPR gene-editing systems, researchers have scoured microbes in everything from hot springs and peat bogs to poo and even yogurt. Now, thanks ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Scientists study a molecular machine that moves jumping genes in DNA, paving the way for a new gene editing tool beyond CRISPR-Cas9. (Nanowerk News) More than a decade ago, scientists harnessed a ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

We performed both homology-based and GUIDE-seq nomination of candidate off-target sites, which resulted in the testing of 5002 sites from four healthy donors (not shown). We then nominated additional ...

CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...